Tokenized equities platform Dinari said it has opened onchain trading to eligible US investors, enabling purchases and sales of all S&P 500 constituents using USDC from self-custody crypto wallets. The rollout covers more than 700 US stocks. Dinari said it is the first US-authorized tokenized equity platform, and the move allows US individuals and businesses to participate without a traditional brokerage account.

Amara Raja Energy & Mobility reported consolidated net profit of ₹191 crore for the June quarter, up 15.8% year on year. Revenue from operations rose 24% to ₹4,214.5 crore, while EBITDA increased 11.7% to ₹405.9 crore and the EBITDA margin narrowed to 9.6% from 10.7%. New energy business revenue grew to ₹209.30 crore from ₹121.29 crore. After the results, the stock fell 2.82%.

Robinhood has launched zero-commission crypto trading in the UK through Bitstamp, offering access to more than 50 cryptocurrencies. Users will pay a 0.1% foreign-exchange fee, which can rise to 0.3% for certain weekend conversions. The news lifted HOOD shares 0.77% to above $94 after the stock closed up 2.84% on Friday. Robinhood’s Q2 results beat expectations, but crypto transaction revenue fell to $100 million, while Bernstein kept a $160 price target.

Memecoin TUT posted more than $42 million in liquidations over the past 24 hours, surpassing Bitcoin and Ethereum to rank as the most liquidated crypto asset. The token had jumped more than 1,100% in two days, hitting an all-time high of $0.2903 on August 9 before reversing sharply. It is now trading about 42% below that peak and saw unusually heavy derivatives activity, with 24-hour futures volume reaching $3.34 billion.

Bubblemaps rose 178.2% as USD 382.30 million in 24-hour volume pushed turnover to 13.80x market cap, with no confirmed same-day project catalyst.

Tutorial (TUT) rose 55.5% in 24 hours as USD 695.4 million turnover and reported liquidations amplified a high-risk BNB Chain momentum move.

MUBARAK is up 44.5% in 24 hours as USD 136.27 million volume produced 5.49x turnover; the move reads as high-turnover market structure.

Oculis has signed an asset purchase agreement with Accure Therapeutics to acquire the worldwide development and commercial rights to Privosegtor and, in a separate closing, ACT02. The consideration includes a $3.8 million upfront cash payment and up to 2,050,000 Oculis ordinary shares, with lockup and milestone-based vesting terms. Privosegtor is an investigational neuroophthalmology drug candidate that has not received regulatory approval for commercial use in any country, while ACT02 is an early-stage preclinical neurology candidate. Oculis said the deal is intended to strengthen its pipeline and strategic position in neuroophthalmology.